NUVB - Quick Take - ROS1 Rejuvenated: We See Upside to NUVB's Current Valuation Following GSK's Acquisition of ROS1 Comp, NUVL

Research evidence excerpt

NUVB - Quick Take - ROS1 Rejuvenated: We See Upside to NUVB's Current Valuation Following GSK's Acquisition of ROS1 Comp, NUVL

Truist Securities

Buy (B) – the stock’s total return is expected to outperform the S&P 500 or relevant benchmark over the next 12-18 months (unless

otherwise indicated)

Hold (H) – the stock’s total return is expected to perform in line with the S&P 500 or relevant benchmark over the next 12-18 months

(unless otherwise indicated)

Sell (S) – the stock’s total return is expected to underperform the S&P 500 or relevant benchmark over the next 12-18 months (unless

Not Rated (NR) – Truist Securities does not have an investment rating or opinion on the stock

Coverage Suspended (CS) – indicates that Truist Securities’ rating and/or target price have been temporarily suspended due to

applicable regulations and/or Truist Securities Management discretion. The previously published rating and target price should not be

relied upon.

Truist Securities analysts have a price target on the stocks that they cover, unless otherwise indicated. The price target represents

that analyst's expectation of where the stock will trade in the next 12-18 months (unless otherwise indicated). If an analyst believes

that there are insufficient valuation drivers and/or investment catalysts to derive a positive or negative investment view, they may elect

with the approval of Truist Securities Research Management not to assign a target price; likewise certain stocks that trade under $5

may exhibit volatility whereby assigning a price target would be unhelpful to making an investment decision. As such, with Research

Management‘s approval, an analyst may refrain from assigning a target to a sub-$5 stock.

Legend for Rating and Price Target History Charts:

B = Buy

H = Hold

S = Sell